BEACON Study: Brepocitinib Associated with 69% Skin Clearance Rate in Cutaneous Sarcoidosis

The oral tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor brepocitinib significantly improved cutaneous sarcoidosis disease activity compared with placebo in a phase 2 randomized clinical trial published in JAMA Dermatology.

Brepocitinib Efficacy and Safety in Cutaneous Sarcoidosis

The double-blind dose-ranging portion of the BEACON trial included 31 adults (mean age, 53.3 years; 58% female), randomly assigned to once-daily brepocitinib 45 mg (n = 13), brepocitinib 15 mg (n = 11), or placebo (n = 7). The primary endpoint was change from baseline in Cutaneous Sarcoidosis Activity and Morphology Instrument–Activity (CSAMI-A) scores at week 16.

Both doses reduced disease activity, with mean CSAMI-A improvements of 22.3 and 22.2 points, respectively, vs 0.7 points for placebo (P < 0.001). Treatment effects were evident by week 4.

At week 16, 69.2% of patients receiving brepocitinib 45 mg achieved clear or almost clear disease, compared with none receiving placebo (P = 0.01). Additionally, 76.9% achieved at least a 50% reduction in CSAMI-A scores versus 0% with placebo (P = 0.003).

Adverse events occurred in 92%, 82%, and 86% of patients receiving 45 mg, 15 mg, and placebo, respectively. No serious adverse events or deaths occurred.

Limitations affecting applicability included the limited treatment duration and small sample size. 

"In this phase 2 randomized clinical trial, brepocitinib demonstrated rapid, dose-dependent, and clinically meaningful improvements in CS disease activity alongside favorable effects on cutaneous remission–oriented efficacy end points and skin-related quality of life," the authors concluded.

Source

Rosenbach M, et al. JAMA Dermatology. 2026. Doi:10.1001/jamadermatol.2026.5444